Acute kidney injury in patients with cancer
MH Rosner, MA Perazella - New England Journal of Medicine, 2017 - Mass Medical Soc
Acute Kidney Injury in Patients with Cancer | New England Journal of Medicine Skip to main
content The New England Journal of Medicine homepage Advanced Search SEARCH …
content The New England Journal of Medicine homepage Advanced Search SEARCH …
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
Summary Here, the International Myeloma Working Group (IMWG) updates its clinical
practice recommendations for the management of multiple myeloma-related renal …
practice recommendations for the management of multiple myeloma-related renal …
NCCN guidelines insights: Multiple myeloma, version 1.2020: Featured updates to the NCCN guidelines
SK Kumar, NS Callander, J Hillengass… - Journal of the National …, 2019 - jnccn.org
The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis,
workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy …
workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy …
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Abstract Continuous lenalidomide-dexamethasone (Rd)-based regimens are among the
standards of care in transplant-ineligible newly diagnosed multiple myeloma (NDMM) …
standards of care in transplant-ineligible newly diagnosed multiple myeloma (NDMM) …
Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical …
F Bridoux, PL Carron, B Pegourie, E Alamartine… - Jama, 2017 - jamanetwork.com
Importance Cast nephropathy is the main cause of acute kidney injury in multiple myeloma
and persistent reduction in kidney function strongly affects prognosis. Strategies to rapidly …
and persistent reduction in kidney function strongly affects prognosis. Strategies to rapidly …
Current approaches to management of newly diagnosed multiple myeloma
Major developments in the treatment of multiple myeloma (MM) over the past decade have
led to a continued improvement in survival. Significant progress has been made with deeper …
led to a continued improvement in survival. Significant progress has been made with deeper …
High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised …
CA Hutchison, P Cockwell, V Moroz… - The Lancet …, 2019 - thelancet.com
Background In multiple myeloma, severe acute kidney injury due to myeloma cast
nephropathy is caused by pathogenic free light chain immunoglobulin in serum. High cutoff …
nephropathy is caused by pathogenic free light chain immunoglobulin in serum. High cutoff …
Management of acute kidney injury in symptomatic multiple myeloma
F Bridoux, N Leung, M Belmouaz, V Royal, P Ronco… - Kidney international, 2021 - Elsevier
Symptomatic multiple myeloma is commonly complicated by acute kidney injury through
various mechanisms. The most frequent is the precipitation of monoclonal free light chains …
various mechanisms. The most frequent is the precipitation of monoclonal free light chains …
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) …
Over the last two decades, the utilization of various novel therapies in the upfront or salvage
settings has continued to improve survival outcomes for patients with Multiple Myeloma …
settings has continued to improve survival outcomes for patients with Multiple Myeloma …
[HTML][HTML] From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
F Gay, M Engelhardt, E Terpos, R Wäsch… - …, 2018 - ncbi.nlm.nih.gov
Survival of myeloma patients has greatly improved with the use of autologous stem cell
transplantation and novel agents, such as proteasome inhibitors, immunomodulatory drugs …
transplantation and novel agents, such as proteasome inhibitors, immunomodulatory drugs …